@article{ef760f8c73cf40a1a107e4defb5e8b45,
title = "Safety and Pharmacodynamics of the PDE4 Inhibitor Roflumilast in Advanced B-cell Malignancies",
author = "\{Mejia Garcia\}, \{Alex V.\} and \{and institutional affiliations\}, \{Additional authors\}",
note = "Purpose: In this study, we aimed to validate our extensive preclinical data on phosphodiesterase 4 (PDE4) as actionable target in B-cell malignancies. Our specific objectives were to determine the safety, pharmacokinetics, and pharmacodynamics (PI3K/AKT activity), as well as to capture any po ... Kelly, K., Mejia, A., Suhasini, A. N., Lin, A. P., Kuhn, J., Karnad, A. B., Weitman, S., \& Aguiar, R. C. (2017). Safety and Pharmacodynamics of the PDE4 Inhibitor Roflumilast in Advanced B-cell Malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research, 23(5), 1186–1192. https://doi.org/10.1158/1078-0432.CCR-16-1207",
year = "2017",
language = "American English",
volume = "23",
journal = "Clinical Cancer Research",
}